Valuation: Genmab A/S

Market Cap 126B 19.45B 16.8B 15.81B 14.37B 27.02B 1,864B 27.42B 185B 72.67B 932B 73.04B 71.45B 3,105B P/E 2026 *
26.6x
P/E 2027 * 18.7x
Enterprise Value 145B 22.49B 19.43B 18.28B 16.61B 31.25B 2,155B 31.7B 214B 84.02B 1,078B 84.45B 82.61B 3,590B EV / Sales 2026 *
5.01x
EV / Sales 2027 * 4.06x
Free-Float
95.42%
Yield 2026 *
-
Yield 2027 * -
1 day+0.83%
1 week+4.12%
Current month+14.12%
1 month+14.83%
3 months+28.00%
6 months+18.39%
Current year+4.64%
1 week 2,005
Extreme 2005
2,134
1 month 1,819.5
Extreme 1819.5
2,134
Current year 1,512
Extreme 1512
2,257
1 year 1,512
Extreme 1512
2,257
3 years 1,157
Extreme 1157
2,710
5 years 1,157
Extreme 1157
3,327
10 years 786.2
Extreme 786.2
3,327
Manager TitleAgeSince
Chief Executive Officer 65 2010-05-31
Director of Finance/CFO 48 2020-02-29
Chief Tech/Sci/R&D Officer - 2024-08-15
Director TitleAgeSince
Director/Board Member 75 2003-10-31
Director/Board Member 58 2014-12-31
Director/Board Member 75 2014-12-31
Date Insider Type Main position Quantity % Market Cap.
12/1/25 Fiscal year

Director

189 0.0003%
12/1/25 Fiscal year

Director

189 0.0003%
12/1/25 Fiscal year

Director

283 0.0004%
Change 5-day change 1-year change 3-year change Capi.($)
+0.83%+4.12%+39.95%-14.99% 19.45B
+0.17%+4.35%+72.39%+114.97% 73.45B
+0.30%+14.64%+56.06%+91.27% 62.99B
+0.11%-3.10%+0.94%+491.16% 28.05B
-1.52%+4.68%+60.64%+20.20% 25.42B
+1.26%-0.05%-17.59%-15.96% 23.3B
-0.71%-4.11%+243.99%+423.83% 18.16B
-3.41%-0.85%+14.91%+516.47% 16.53B
+1.53%+3.49%+40.68%+151.75% 13.16B
-0.90%-1.50%+341.49%+211.04% 12.42B
Average -0.24%+2.19%+85.35%+198.98% 29.29B
Weighted average by Cap. -0.07%+4.69%+69.08%+166.17%

Financials

2026 *2027 *
Net sales 29.01B 4.49B 3.88B 3.65B 3.32B 6.24B 430B 6.33B 42.83B 16.78B 215B 16.87B 16.5B 717B 33.71B 5.22B 4.51B 4.24B 3.86B 7.25B 500B 7.36B 49.76B 19.5B 250B 19.6B 19.18B 833B
Net income 4.94B 765M 661M 622M 565M 1.06B 73.32B 1.08B 7.29B 2.86B 36.67B 2.87B 2.81B 122B 7.17B 1.11B 960M 903M 821M 1.54B 106B 1.57B 10.59B 4.15B 53.24B 4.17B 4.08B 177B
Net Debt 19.62B 3.04B 2.62B 2.47B 2.24B 4.22B 291B 4.28B 28.97B 11.35B 146B 11.41B 11.16B 485B 11.13B 1.72B 1.49B 1.4B 1.27B 2.39B 165B 2.43B 16.43B 6.44B 82.6B 6.47B 6.33B 275B
Logo Genmab A/S
Genmab A/S specializes in the research and development of human and therapeutic antibodies intended for treating cancers, infectious diseases, rheumatoid arthritis, etc. Net sales break down by type of income as follows: - royalties (83.4%); - income from sales of products (10.7%); - other (5.9%): primarily income from partnership agreement. Net sales are distributed geographically as follows: Denmark (89.4%), the United States (4.9%) and Japan (5.7%).
Employees
3,119
Date Price Change Volume
26-08-19 DKK 2,114.00 +0.48% 3,774
26-08-18 DKK 2,104.00 0.00% 108,957
26-08-17 DKK 2,104.00 +3.80% 177,078
26-08-14 DKK 2,027.00 +0.10% 102,525
26-08-13 DKK 2,025.00 -0.59% 103,599
Trader
Investor
Global
Quality
ESG MSCI
A
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
18
Last Close Price
2,104.00DKK
Average target price
2,410.59DKK
Spread / Average Target
+14.57%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. GMAB Stock